Related Experiment Videos
Development of a hybrid artificial intelligence framework for pharmacotherapy optimization
Olaf Rose1,2, Stephanie Clemens3,4, Andreas Leiherer5
1Institute of Pharmacy, Pharmaceutical Biology and Clinical Pharmacy, Paracelsus Medical University, Strubergasse 15, 5020, Salzburg, Austria. olaf.rose@pmu.ac.at.
Introduction:
Pharmacotherapy optimization in multimorbid patients is increasingly complex due to polypharmacy, fragmented data, expanding electronic health records, and workforce constraints. Conventional clinical decision support systems remain largely rule-based and often fail to adequately incorporate patient-specific context. While artificial intelligence offers new opportunities, stand-alone models remain insufficiently reliable for high-risk pharmacotherapy decision support.
Aim:
To develop a relevance-driven, clinician-supervised hybrid AI framework for pharmacotherapy optimization.
Method:
Using a design science-informed approach, an interdisciplinary research group developed a conceptual framework for AI-supported pharmacotherapy optimization. Framework development was informed by prior feasibility work, published literature, clinical practice requirements, and iterative interdisciplinary discussions. Hybrid AI was defined as the combination of retrieval-augmented generation, deterministic safety rules, and large language model reasoning.
Results:
Seven design principles were identified, including decomposition of clinical activities, relevance-based prioritization, hybrid reasoning under clinician oversight, integration of patient goals, transparency of evidence sources, longitudinal optimization within a governed closed loop, and evaluation as a design requirement. These principles informed a conceptual architecture integrating structured clinical data, patient preferences, longitudinal patient information, and evidence retrieval within a clinician-governed decision-support framework.
Conclusion:
The proposed framework conceptualizes AI as a relevance-structuring, clinician-governed decision-support layer rather than an autonomous decision-maker. By combining hybrid reasoning, patient-specific context, and professional oversight, it provides a conceptual foundation for future development, implementation, and evaluation of AI-supported pharmacotherapy systems.
Related Concept Videos
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Drug Discovery: Overview
Pharmacodynamic Models: Overview
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...